Reactions Weekly

, Volume 1206, Issue 1, pp 5–5 | Cite as

Rosiglitazone [Avandia] does not increase the risk of cardiovascular mortality and morbidity in patients with type 2 diabetes mellitus

Media release


Glucose Diabetes Mellitus Heart Disease Cardiovascular Event Veteran Affair 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    GlaxoSmithKline.Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R). Media Release: 9 Jun 2008. Available from: URL:

Copyright information

© Adis International limited or Adis Data Information BV 2008

Personalised recommendations